Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Rare Revolution Magazine focuses on newborn screening (NBS) in recent issue co-sponsored by Travere Therapeutics